Literature DB >> 6352626

The pharmacokinetics of ceftazidime in normal and impaired renal function.

D Höffler, P Koeppe, K J Williams.   

Abstract

The concentration of ceftazidime in serum and urine was measured in ten healthy volunteers and 19 patients with renal impairment following a 2 g iv dose of ceftazidime. In impaired renal function the elimination rate of ceftazidime is decreased considerably, whereupon the area under the curve (AUC) rises sharply. Dose reduction factors (DRF) for several degrees of renal function are presented. The urinary recovery decreases with renal function; but therapeutic urine levels can still be detected in patients on dialysis. Patients with renal insufficiency should be given reduced dosage according to a dose reduction factor and according to the table.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6352626     DOI: 10.1093/jac/12.suppl_a.241

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis.

Authors:  Angela S Loo; Michael Neely; Evan J Anderson; Cybele Ghossein; Milena M McLaughlin; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

2.  Kinetics of ceftazidime during plasmapheresis.

Authors:  F Bozkurt; P Schollmeyer; E Keller
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  Population pharmacokinetics of continuous infusion ceftazidime.

Authors:  B C Frame; B F Facca; D P Nicolau; S N Triesenberg
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

4.  Pharmacokinetics of ceftazidime in acutely ill hospitalised elderly patients.

Authors:  M Jonsson; M Walder
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267

5.  The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy.

Authors:  R A Walstad; K Dahl; K B Hellum; E Thurmann-Nielsen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Correlation of the pharmacokinetic parameters of amikacin and ceftazidime.

Authors:  Duangchit Panomvana; Sam-Ang Kiatjaroensin; Danabhand Phiboonbanakit
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 8.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

Review 9.  Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Hemodialysis.

Authors:  Christo Cimino; Yvonne Burnett; Nikunj Vyas; Anne H Norris
Journal:  Drugs       Date:  2021-02-16       Impact factor: 11.431

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.